Products
Tropisetron was approved in many countries starting in 1992 as a solution for injection and in capsule form (Navoban). It was withdrawn from the market in 2013.
Structure and properties
Tropisetron (C17H20N2O2, Mr = 284.4 g/mol) is an indole and tropane derivative. It exists as a white powder that is soluble in water.
Effects
Tropisetron (ATC A04AA03) is antiemetic. It is a potent, selective, and competitive sertotonin antagonist at the 5-HT3 receptor in the peripheral and central nervous system.
Indications
For the prevention of nausea and vomiting in patients undergoing cytostatic cancer chemotherapy. For the treatment of nausea and vomiting after surgery.
Dosage
According to the SmPC. The solution for injection is administered intravenously. Capsules are taken in the morning after rising at least 1 hour before breakfast with some water. Food may increase bioavailability slightly, by up to 20%.
Contraindications
Tropisetron is contraindicated in hypersensitivity and during pregnancy. For complete precautions, see the drug label.
Interactions
Drugs that prolong the QT interval should be used concomitantly with caution. Enzyme-inducing agents such as rifampicin and phenobarbital may decrease tropisetron plasma levels.
Adverse Effects
The most common possible adverse effects include headache, dizziness, fatigue, constipation, diarrhea, and abdominal pain. Occasionally, hypersensitivity reactions have been reported.
